TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9669750

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 antifactor Xa units subcutaneously once daily for 35 days)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo injections for 28 days after 7 days of dalteparin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: COMPARATOR
Intervention: Dalteparin and Placebo
Number of subjects: 281
Study: 8166218

Group type: EXPERIMENTAL
Intervention: Residual disease < 2 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Residual disease 2 to 2.9 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Residual disease 3 to 3.9 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Residual disease 4 to 5.9 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Residual disease 6 to 7.9 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Residual disease 8 to 9.9 cm
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: > or = 10 cm residual disease
Number of subjects: 294

Group type: COMPARATOR
Intervention: > or = 2 cm residual disease
Number of subjects: 294
Study: 3349555

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 (Group V)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.25 mg.kg‐1 and 0.3 mg.kg‐1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 to 0.2 mg.kg‐1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Groups IV and VI
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 77
Study: 30045292

Group type: EXPERIMENTAL
Intervention: Early hand washing group (hand washing during field training starting in the first week)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Late hand washing group (no hand washing for the first 2 weeks, began in the third week)
Number of subjects: 1291
Study: 28376912

Group type: EXPERIMENTAL
Intervention: csDMARD plus glucocorticoid therapy (methotrexate + sulphasalazine + hydroxychloroquine + i.a. glucocorticoids or methotrexate + prednisolone p.o.)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: methotrexate + certolizumab-pegol
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: methotrexate + abatacept
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: methotrexate + tocilizumab
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Immediate tapering
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Delayed tapering (after 24 weeks)
Number of subjects: 800
Study: 25750586

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study: 23017620

Group type: EXPERIMENTAL
Intervention: Involved family vignette
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Nonreligious objections vignette
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Fear of being sued
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Personal distress and perception of futile care
Number of subjects: 364
Study: 20885197

Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program (ES): 240 ± 121 minutes of running plus 2 strength training sessions per week (120 minutes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Endurance running (E): 276 ± 108 minutes running per week
Number of subjects: 22
Study: 18769979

Group type: EXPERIMENTAL
Intervention: EBM teaching
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no EBM teaching)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EBM group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 16792454

Group type: COMPARATOR
Intervention: Somatostatin (SMT) 250 mg/h
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somatostatin (SMT) 500 mg/h
Number of subjects: 62
Study: 14557107

Group type: EXPERIMENTAL
Intervention: Bayesian methodology incorporating prior beliefs about selection bias parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis for treatment comparisons
Number of subjects: 0
Study: 10692276

Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Number of subjects: 99
Study: 9181154

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 micrograms/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous morphine (30 micrograms/kg) with PCA
Number of subjects: 20
Study: 1287560

Group type: EXPERIMENTAL
Intervention: High-protein diet (150 kcal/kg/d with 15% of calories as protein)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isocaloric control diet (6% of calories as protein)
Number of subjects: 22
Study: 3981479

Group type: EXPERIMENTAL
Intervention: High demand task
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low demand task
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (baseline sessions)
Number of subjects: 45
Study: 31903654

Group type: EXPERIMENTAL
Intervention: IMB-based programme (n = 15)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 35
Study: 29466911

Group type: EXPERIMENTAL
Intervention: Study 1 (Time2bHealthy)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Study2Diet
Number of subjects: 119

Group type: COMPARATOR
Intervention: Study2PA
Number of subjects: 119

Group type: COMPARATOR
Intervention: Study2Combo
Number of subjects: 119
Study: 26607637

Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 970

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 970
Study: 25636291

Group type: EXPERIMENTAL
Intervention: Xinjingjie mouthrinse (5 mL, 4 times daily during radiotherapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study: 22373953

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (400mg) daily
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Ground fish (529±109mg) daily
Number of subjects: 647

Group type: COMPARATOR
Intervention: Control group (no calcium supplementation, received vitamin A as placebo)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (both forms)
Number of subjects: 647
Study: 20202290

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in saturated fat
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fat
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet with very long-chain n-3 PUFA supplementation
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet without very long-chain n-3 PUFA supplementation
Number of subjects: 486
Study: 18978320

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 273
Study: 15742593

Group type: EXPERIMENTAL
Intervention: Preoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Postoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Number of subjects: 22
Study: 14569937

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: R-CHOP chemotherapy
Number of subjects: 33
Study: 10873691

Group type: EXPERIMENTAL
Intervention: Two-view mammography
Number of subjects: 110

Group type: COMPARATOR
Intervention: One-view mammography
Number of subjects: 110
Study: 8636761

Group type: EXPERIMENTAL
Intervention: 4 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 6 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 6 mg TNF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4 mg TNF
Number of subjects: 38
Study: 1346121

Group type: EXPERIMENTAL
Intervention: Advice to reduce alcohol consumption
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 41
Study: 3873661

Group type: EXPERIMENTAL
Intervention: Electrode size 3 x 3 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Electrode size 6 x 6 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Electrode size 9 x 9 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Electrode size 5 x 16.2 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Larger electrodes (6 x 6 cm and 9 x 9 cm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All electrode sizes
Number of subjects: 14
Study: 30392472

Group type: EXPERIMENTAL
Intervention: Carbohydrate counting (Intervention Group)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Traditional nutritional advice (Control Group)
Number of subjects: 286
Study: 29884212

Group type: EXPERIMENTAL
Intervention: TEAMS training (8-week program)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TEAMS training
Number of subjects: 67
Study: 27604504

Group type: EXPERIMENTAL
Intervention: Optimal supportive care (OSC) plus whole brain radiotherapy (WBRT) (20 Gy in five daily fractions)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Optimal supportive care (OSC) alone
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Both groups (OSC plus WBRT and OSC alone)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: OSC plus WBRT
Number of subjects: 538

Group type: COMPARATOR
Intervention: OSC alone
Number of subjects: 538
Study: 24606627

Group type: EXPERIMENTAL
Intervention: Remote examiner (RE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local examiner (LE)
Number of subjects: 40
Study: 21703594

Group type: EXPERIMENTAL
Intervention: Didactic lecture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Second Life
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simulated operating suite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 20852176

Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 28

Group type: COMPARATOR
Intervention: SOE (Intralipid 20%)
Number of subjects: 28
Study: 17432643

Group type: EXPERIMENTAL
Intervention: Deeply needling Ciliao (BL 32) plus routine acupoints
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine acupoints only
Number of subjects: 180
Study: 15692120

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: IMT >1 mm after mean follow-up of 46 months
Number of subjects: 642
Study: 11820420

Group type: EXPERIMENTAL
Intervention: Flutter valve drainage bag
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional underwater seal system
Number of subjects: 50
Study: 9564295

Group type: EXPERIMENTAL
Intervention: Sandwich group (fibrin glue sandwich technique)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sealing group (fibrin glue sealing technique)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sandwich group (fibrin glue sandwich technique) for gastric malignancy patients
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sealing group (fibrin glue sealing technique) for gastric malignancy patients
Number of subjects: 111
Study: 8042889

Group type: EXPERIMENTAL
Intervention: Case management intervention with educational materials and follow-up calls within 24 hours of discharge.
Number of subjects: 668

Group type: COMPARATOR
Intervention: Control group (standard care without case management intervention).
Number of subjects: 668
Study: 3113245

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times daily for seven days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Misoprostol vs Placebo
Number of subjects: 45
Study: 31407414

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (IMIQ)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Diclofenac 3% gel (DIC)
Number of subjects: 479
Study: 28792791

Group type: EXPERIMENTAL
Intervention: JoyBar control
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard joystick control
Number of subjects: 27
Study: 26840968

Group type: EXPERIMENTAL
Intervention: Bedside teaching rounds
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nonbedside teaching rounds
Number of subjects: 107
Study: 24956324

Group type: EXPERIMENTAL
Intervention: Home-based community health worker (CHW) delivered diabetes self-management intervention
Number of subjects: 287

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 287
Study: 23889940

Group type: EXPERIMENTAL
Intervention: MgSO(4) 70 mg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 56
Study: 21564049

Group type: EXPERIMENTAL
Intervention: McGrath(®) videolaryngoscope
Number of subjects: 80

Group type: COMPARATOR
Intervention: Henderson straight blade laryngoscope
Number of subjects: 80
Study: 19231315

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Simvastatin (20 to 40 mg/day)
Number of subjects: 8888
Study: 16805922

Group type: EXPERIMENTAL
Intervention: Pro-adrenomedullin (proADM) levels
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Pro-adrenomedullin (proADM)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Clinical model including PSI and proADM
Number of subjects: 302
Study: 12812657

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg and letrozole (2.5 mg) orally q.d. for 8 weeks
Number of subjects: 191

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg and exemestane (25 mg) orally q.d. for 8 weeks
Number of subjects: 191
Study: 10997396

Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Double antiretroviral therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both double and triple therapies
Number of subjects: 26
Study: 9051062

Group type: EXPERIMENTAL
Intervention: 6-month regimen (4S3H3R3Z3/2H3R3)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 9-month regimen (4S3H3R3Z3/5H3R3)
Number of subjects: 91
Study: 8159300

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CsA) 5 mg/kg/day in adults, 6 mg/kg/day in children for 9 months, tapered off by 25% every month until complete discontinuation at month 12
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyclophosphamide 2.5 mg/kg/day for 8 weeks
Number of subjects: 66
Study: 6689183

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 8
Study: 31188421

Group type: EXPERIMENTAL
Intervention: Vein-First Surgical Technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: Artery-First Surgical Technique
Number of subjects: 86
Study: 29579042

Group type: EXPERIMENTAL
Intervention: Mesalamine treatment (multiple doses over 6 weeks)
Number of subjects: 457
Study: 26645793

Group type: EXPERIMENTAL
Intervention: Integrated Personalized Diabetes Management (PDM)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 1014
Study: 25049132

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei subsp paracasei L. casei W8 (10^9 CFU)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei subsp paracasei L. casei W8 (10^10 CFU)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 21
Study: 23138078

Group type: EXPERIMENTAL
Intervention: In-home monitoring intervention via broadband communication device with care coordinator nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care from GP
Number of subjects: 0
Study: 21129226

Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 17610346

Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulant therapy (including a teaching program for self-management followed by 6 months of independent self-management)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional management (6 months of standard care)
Number of subjects: 92
Study: 16944823

Group type: EXPERIMENTAL
Intervention: Positioning procedure (two 30-min sessions a day, five days a week, for five weeks)
Number of subjects: 19
Study: 15250178

Group type: EXPERIMENTAL
Intervention: Multiple presentations of phonological associates (1, 2, or 3 times) during study in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five repetitions of phonological associates during study in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two study presentations of critical test words in Experiment 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control lures (not specified in detail)
Number of subjects: 0
Study: 11013363

Group type: EXPERIMENTAL
Intervention: 2-cm excision margin
Number of subjects: 989

Group type: COMPARATOR
Intervention: 5-cm excision margin
Number of subjects: 989
Study: 9001829

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 1108
Study: 1518313

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation letter
Number of subjects: 73

Group type: COMPARATOR
Intervention: No consultation
Number of subjects: 73
Study: 6828828

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programme including diet therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 133
Study: 26823382

Group type: EXPERIMENTAL
Intervention: Feed-Forward Modeling (FFM) system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpharmacological community care intervention
Number of subjects: 0
Study: 31352180

Group type: EXPERIMENTAL
Intervention: Serious games intervention (12 supervised sessions, 45 minutes each) aimed at improving the most affected upper limb.
Number of subjects: 18
Study: 27858685

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT), applied once a week for three weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 60
Study: 25196239

Group type: EXPERIMENTAL
Intervention: 10-week group intervention 'Living Well with Dementia'
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting-list control (treatment as usual)
Number of subjects: 58
Study: 24060951

Group type: EXPERIMENTAL
Intervention: Synbiotics preparation for one month
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22185091

Group type: EXPERIMENTAL
Intervention: Laparoscopic technique for PD catheter insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open technique for PD catheter insertion
Number of subjects: 0
Study: 19101098

Group type: EXPERIMENTAL
Intervention: Methadone dose increase (100mg/day) with split contingency
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Methadone dose increase (70mg/day) with split contingency
Number of subjects: 252

Group type: COMPARATOR
Intervention: Noncontingent control group (100mg/day)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Contingent on cocaine-negative urines
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Standard treatment during 5-week baseline
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Active intervention groups
Number of subjects: 252
Study: 17345784

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (Rosiglitazone 4 mg/day)
Number of subjects: 188
Study: 14659863

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors (abciximab) administered intravenously, along with heparin and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo administered with full dose of rtpA (100 mg) and standard heparin treatment and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors (abciximab)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10780137

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 21
Study: 9265549

Group type: EXPERIMENTAL
Intervention: Greater involvement in care (experimental group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 31
Study: 1458389

Group type: EXPERIMENTAL
Intervention: NG decompression
Number of subjects: 102

Group type: COMPARATOR
Intervention: No NG decompression
Number of subjects: 102
Study: 6485854

Group type: EXPERIMENTAL
Intervention: 0.05 mg glucagon/kg body weight intramuscularly before attempts at reduction
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no glucagon before reduction attempts)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (after 3 unsuccessful attempts)
Number of subjects: 188
Study: 31671592

Group type: EXPERIMENTAL
Intervention: Novel smartphone application accessed weekly from week 1 to week 6
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group accessed the application after week 6
Number of subjects: 8
Study: 30462806

Group type: EXPERIMENTAL
Intervention: sHT-Tr (exercise training group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: sHT-Sed (control group)
Number of subjects: 20
Study: 26687391

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m², once every 21 days) plus best supportive care
Number of subjects: 148

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pemetrexed group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 148
Study: 25180609

Group type: EXPERIMENTAL
Intervention: 2 L polyethylene glycol plus ascorbate (PEG+Asc)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 356
Study: 22663197

Group type: EXPERIMENTAL
Intervention: Food-simulating liquid (FSL) - citric acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Food-simulating liquid (FSL) - ethanol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (air)
Number of subjects: 6